Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Forterra Environmental Corp FEVCF



GREY:FEVCF - Post by User

Post by MoneyMaker110on May 11, 2010 10:20am
581 Views
Post# 17084096

GOOD MONEY TO BE MADE

GOOD MONEY TO BE MADE

WATCH FOR A RISE IN THE STOCK. A PRE ANNOCUMENT CAN ONLY BE A GREAT SIGN TO COME.  COULD POP OVER 0.50 OR HIGHER.  YEARS AGO IT HAD A PRE ANNOCUMENT AND IT HAD POPPED FROM .19 TO 1.13.  QUICK MONEY TO BE MADE.


PharmaGap Inc. (TSX VENTURE:GAP) (OTCBB:PHRGF) ("PharmaGap" or "the Company") is pleased to announce that it has now received results of testing of its lead cancer drug GAP-107B8, at the National Cancer Center ("NCI") in Bethesda, MD, and is currently in the final stages of analyzing the data generated. Results will be announced in a few days.

Late last year the NCI tested the Company's lead cancer drug in the NCI's 60 cell human cancer tumour panel at a single dose concentration of 10 micromolars, and in a 5 dose range of up to 100 micromolars. The results of these tests were previously reported. After discussion with the Company, the NCI undertook a further testing program at a much narrower dose range of 5 micromolar to 80 micromolar concentration, consistent with previous in vitro testing of GAP-107B8 and consistent with established effective dose ranges for peptide drug compounds.

This test program began in January. Initial test results were made available to the Company in the first quarter. At the NCI's initiative, this test was run a second time to confirm the earlier findings, and the Company has now received the data from these tests. These latest test results will be announced within a few days following completion of analysis.

The Company has also been advised by SC Stormont Inc. ("Stormont") that Stormont has retained Mr. Martin Tremblay to provide investor relations services to PharmaGap as part of the Strategic Leadership Agreement between PharmaGap and Stormont.

<< Previous
Bullboard Posts
Next >>